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The emergence and spread of antibiotic-resistant bacteria is pushing the need of
alternative treatments. In this context, phage therapy is already a reality to successfully
fight certain multiresistant bacteria. Among different phage gene products, murein
hydrolases responsible of phage progeny liberation (also called lysins or endolysins)
are weapons that target specific peptidoglycan bonds, leading to lysis and death of
susceptible bacteria when added from the outside. In the pneumococcal system, all
but one phage murein hydrolases reported to date share a choline-binding domain
that recognizes cell walls containing choline residues in the (lipo)teichoic acids. Some
purified pneumococcal or phage murein hydrolases, as well as several chimeric
proteins combining natural catalytic and cell wall-binding domains (CBDs) have been
used as effective antimicrobials. In this work we have constructed a novel chimeric
N-acetylmuramoyl-L-alanine amidase (PL3) by fusing the catalytic domain of the Pal
amidase (a phage-coded endolysin) to the CBD of the LytA amidase, the major
pneumococcal autolysin. The physicochemical properties of PL3 and the bacteriolytic
effect against several pneumococci (including 48 multiresistant representative strain)
and related species, like Streptococcus pseudopneumoniae, Streptococcus mitis, and
Streptococcus oralis, have been studied. Results have shown that low doses of PL3, in
the range of 0.5–5 µg/ml, are enough to practically sterilize all choline-containing strains
tested. Moreover, a single 20-µg dose of PL3 fully protected zebrafish embryos from
infection by S. pneumoniae D39 strain. Importantly, PL3 keeps 95% enzymatic activity
after 4 weeks at 37◦C and can be lyophilized without losing activity, demonstrating
a remarkable robustness. Such stability, together with a prominent efficacy against a
narrow spectrum of human pathogens, confers to PL3 the characteristic to be an
effective therapeutic. In addition, our results demonstrate that the structure/function-
based domain shuffling approach is a successful method to construct tailor-made
endolysins with higher bactericidal activities than their parental enzymes.
Keywords: lysin, pneumococcus, phage therapy, chimeric protein, Streptococcus oralis, Streptococcus mitis,
Streptococcus pseudopneumoniae
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INTRODUCTION
Discovery of penicillin and other antibiotics allowed effective
treatment of infectious diseases, which provoked a tremendous
impact on public health. However, it has been learned that sooner
or later bacteria are capable of acquiring resistance to practically
every known antibiotic. This resistance is readily transferred to
other bacteria and, at the end, there is a continuous warfare
between the ability of bacteria to resist any new antimicrobial
and the armamentarium of new weapons to overcome treatment
failures and kill the targeted bacteria. In this context, the use and
abuse of antibiotics in the last years have led to a substantial rise of
bacterial multiresistance and this worrying situation runs parallel
with the scarcity of new antimicrobials in the pharmaceutical
pipeline (Spellberg et al., 2015).
Among the main human pathogens, Streptococcus
pneumoniae continues to be a major cause of morbidity
and mortality worldwide —causing more deaths than any other
infectious disease —being children younger than 5 years old, the
elderly, and immunocompromised people the major groups at
risk. Pneumococcal diseases range from mild infections, such
as otitis media and sinusitis, to more severe diseases such as
pneumonia (either invasive or not), septicemia, and meningitis.
Despite the availability of vaccines and antibiotics, a recent
report estimated that pneumococcus is still responsible for
approximately 1.3 million deaths annually (Walker et al., 2013).
For decades, the standard treatment of pneumococcal infections
has been penicillin, to which this species was exquisitely sensitive.
However, a widespread increase of pneumococci resistant to
most antibiotics (except to vancomycin) has been progressively
observed (Kim et al., 2016). The tendency on the emergence
of multidrug resistance pathogens is an increasingly global
economic and healthcare crisis, and this situation is pushing
to find alternative approaches for combating such pathogens,
S. pneumoniae being one of the more clear examples (Huttner
et al., 2013).
Bacteriophage-encoded lytic enzymes (or endolysins) are
murein hydrolases that selectively break different bonds of
peptidoglycan, thereby enabling the release of progeny virions
at the end of the infection cycle of the majority of double-
stranded DNA bacteriophages. Purified endolysins, and bacterial
autolysins as well, can be applied exogenously to brake the
bacterial cell wall in an effective and selective way. This novel
class of antibacterials, also known as enzybiotics, presents
important advantages over classical antibiotics, e.g., narrow
spectrum of susceptible bacteria, rapid killing of stationary
and logarithmically growing bacteria, and low probability to
bacterial resistance (Pastagia et al., 2013). In addition, lysins can
also eliminate bacteria from mucous membranes and bacterial
biofilms, which are major reservoirs and routes of infection
(Pastagia et al., 2011; Díez-Martínez et al., 2015). Typically, lysins
from Gram-positive bacteria and their bacteriophages consist of a
two-domain structure, but some of them have multiple hydrolytic
domains or distinct types of cell wall-binding domains (CBDs;
Rigden et al., 2003; Nelson et al., 2012). The stringent range
of activity is primarily linked to the specificity of binding of
the CBDs (Hermoso et al., 2007; Gilmer et al., 2013). However,
the net charge of the domains and the fine architecture of the
bacterial envelope contribute as well (Low et al., 2011; Díez-
Martínez et al., 2013). Besides, the intrinsic activity of the catalytic
domain, the strength of attachment to the cell wall, and the
overall protein structure determine the actual lysis rate.
In the last years, several reports of endolysins showing strong
lethal activity against relevant Gram-positive pathogens have
been published, including Staphylococcus aureus (Rashel et al.,
2007; Gilmer et al., 2013), enterococci (Yoong et al., 2004), the
spore formers Bacillus and Clostridium genera (Nakonieczna
et al., 2015), and even some Gram-negative pathogens like
Acinetobacter baumannii (Lood et al., 2015). Specifically in
pneumococcus, endolysins like the Cpl-1 and Cpl-7 lysozymes
and derived chimeras (Díez-Martínez et al., 2013, 2015), or the
Pal N-acetylmuramoyl-L-alanine amidase (NAM-amidase; EC
3.5.1.28; Loeﬄer et al., 2001; Jado et al., 2003) have been proved
to kill efficiently several strains in vitro and in vivo. Moreover,
the bactericidal effect of the major pneumococcal autolysin,
the LytA NAM-amidase, against encapsulated S. pneumoniae
cells has also been demonstrated (Rodríguez-Cerrato et al.,
2007; Díez-Martínez et al., 2013). Pal and LytA have unrelated
catalytic domains belonging to Amidase_5 and Amidase_2
families, respectively, which are fused to homologous choline-
binding domains (66% sequence identity) that anchor to the
phosphocholine residues of pneumococcal (lipo)teichoic acids
(Sheehan et al., 1997). Both choline-binding domains are made
up of six sequence-conserved repeats and a C-terminal tail, where
choline moieties bind at the interface of every two-consecutive
repeats, as deduced by the elucidation of the crystallographic
structures of full-length LytA and its isolated choline-binding
domain (Fernández-Tornero et al., 2001; Li et al., 2015). Besides,
LytA contains a non-canonical choline-binding site in the first
repeat of the choline-binding domain (Mellroth et al., 2014; Li
et al., 2015). Based on the previous structural and functional
knowledge of both NAM-amidases (Varea et al., 2000 and
references therein; Fernández-Tornero et al., 2001; Varea et al.,
2004; Li et al., 2015), we have constructed a novel chimeric
lysin, PL3, by shuﬄing the catalytic domain of Pal with the
choline-binding domain of LytA. PL3 turned out to be a potent
enzybiotic against pneumococci and other choline-containing
Gram-positive pathogens, and its lethality against pneumococcal
encapsulated and multiresistant isolates was higher than those of
the parental enzymes. In addition, in vitro bactericidal activity
of PL3 has also been confirmed in vivo using a zebrafish embryo
infection model.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Bacterial strains used in this study are listed in Table 1.
Pneumococcal cultures were grown at 37◦C without aeration
in C medium supplemented with 0.08% (w/v) yeast extract
(C + Y medium; Lacks and Hotchkiss, 1960). Other Gram-
positive bacteria were grown in brain heart infusion broth
(Becton, Dickinson and Company) at 37◦C without shaking.
Escherichia coli strains were grown in LB medium with aeration
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TABLE 1 | Bacterial strains and plasmids.




F−, ompT, hsdSB (rB− mB−),
gal, dcm, λDE3 (harboring
gene 1 of the RNA
polymerase from the phage






R6 Standard laboratory strain,
non-encapsulated
Hoskins et al., 2001
P046 R6 but lytA, lytC Moscoso et al., 2006
D39 Serotype 2 Lanie et al., 2007
P007 R6 derivative, serotype 3 Domenech et al., 2009
P008 R6 derivative, serotype 4 Moscoso et al., 2006
48 Serotype 23F; penicillin
MIC = 16 mg/ml;
erythromycin
MIC > 128 mg/ml;
ciprofloxacin MIC = 1 mg/ml;
levofloxacin MIC = 1 mg/ml;
chloramphenicol
MIC = 4 mg/ml; tetracycline
MIC > 64 mg/ml
Soriano et al., 2008
Streptococcus mitisT Type strain NCTC 12261
Streptococcus mitis
SK598
Biovar 1 strain with
ethanolamine-containing
C-polysaccharide
Bergström et al., 2003
Streptococcus oralisT Type strain NCTC 11427
Streptococcus
pseudopneumoniaeT
Type strain ATCC BAA-960
Plasmids
pET29a(+) Expression vector; KmR Novagen
pET29-PL3 pET29a(+), pl3; KmR This study
pMSP11 Recombinant plasmid with pal Sheehan et al., 1997
pMMN1 Recombinant plasmid with
lytA
Moscoso et al., 2011
aMIC, minimal inhibitory concentration.
bNCTC, National Collection of Type Cultures; ATCC, American Type Culture
Collection.
at 37◦C, supplemented with kanamycin (Km; 50 µg/ml) when
required.
Cloning, Expression, and Purification of
PL3
The Pal encoding region was PCR amplified with primers
5’Nde_Pal (GGAGGGAAGACATATGGGAGTCGATATTGAA
AAAGG, where the NdeI site is underlined) and 3′GYM_Pal
(CGGTCTGCAAGCATGTAGCCTTGGTCGTCAAAG), using
pMSP11 as template (Sheehan et al., 1997). The LytA
encoding region was PCR amplified with primers 5′LA_LytA
(CTTTGACGACCAAGGCTACATGCTTGCAGACCG) and
3′BamHI_LytA (CGCGGATCCTTATTTTACTGTAATCAAGC
CATCTG, where the BamHI site is underlined) using pMMN1
as template (Moscoso et al., 2011). The resulting PCR products
were used for a third PCR round to amplify the chimeric PL3
encoding gene, which was digested with NdeI and BamHI
and cloned into pET29a(+) previously treated with the same
enzymes. The resulting recombinant plasmid, pET29-PL3, was
sequenced to ensure the accuracy of the insert and transformed
into E. coli BL21(DE3). For overproduction of PL3, transformed
cells were incubated to an optical density at 600 nm (OD600)
of 0.6. Isopropyl-β-D-galactopyranoside (0.1 mM) was then
added, and incubation continued for 4 h at 37◦C. Cells were
harvested by centrifugation (10000 × g, 5 min), resuspended in
20 mM sodium phosphate buffer (hereafter, PB), 0.5 M NaCl,
pH 6.9, disrupted in a French pressure cell and ultracentrifuged
(50000 × g, 45 min) to remove cell debris. Streptomycin sulfate
(Sigma; 2%, w/v) was added to the protein extract and the
mixture was incubated for 15 min at 4◦C with slow stirring to
facilitate DNA precipitation. The insoluble fraction was removed
by ultracentrifugation (50000 × g, 45 min) at 4◦C, and PL3
was purified from the supernatant by affinity chromatography
using DEAE-cellulose (Sanz and García, 1990) followed by size
exclusion chromatography on dextran-agarose (HiLoad 16/60
Superdex 200 PG column, GE Healthcare) to remove large
protein aggregates. Briefly, PL3 fractions eluted from the affinity
column were pooled, dialyzed against PB, pH 6.8, and subjected
to gel filtration using the same buffer at a flow rate of 0.8 ml/min.
The purity and state of the PL3 samples were checked by 12%
SDS-PAGE and mass spectrometry (MALDI-TOF). Large-
aggregate free fractions of PL3 were pooled, dialyzed against PB
containing 100 mM NaCl, 25 mM choline, pH 6.8, and stored
at −20◦C. Before use, the protein was dialyzed against PB, pH
6.8, supplemented with 1 mM β-mercaptoethanol or 10 mM
1,4-dithiothreitol (DTT) when required. PL3 concentration
was determined spectrophotometrically using the theoretical
molar absorption coefficient at 280 nm (133855 M−1 cm−1,
considering cysteine residues in the oxidized state).
Mass Spectrometry
Purified PL3 samples were analyzed by MALDI-TOF in a
Voyager DEPRO (Applied Biosystems), as described elsewhere
(Moreno et al., 2008). A grid voltage of 89%, a 0.25 ion guide
wire voltage, and a delay time of 400 ns in the linear positive-
ion mode were used. External calibration was performed with
carbonic anhydrase (29024 Da) and enolase (46672 Da) from
Sigma, covering an m/z range of 10000–80000 units.
Circular Dichroism (CD)
Circular dichroism spectra were recorded at 20◦C with a J-810
spectropolarimeter (Jasco Corporation) equipped with a Peltier-
type cell holder, using 1-mm (far-UV) or 10-mm (near-UV)
path-length quartz cells and protein concentrations of 0.13 and
0.44 mg/ml, respectively (Bustamante et al., 2010). The buffer
contribution was subtracted from the raw data and the corrected
spectra were converted to mean residue ellipticities (2) using an
average molecular mass per residue of 104.5. Spectra acquisition
and analysis were carried out with the Spectra Manager software.
PL3 titration with choline was performed by measuring
the CD spectra at varying choline concentrations and plotting
the ellipticity variation at selected wavelengths as a function
Frontiers in Microbiology | www.frontiersin.org 3 July 2016 | Volume 7 | Article 1156
fmicb-07-01156 July 26, 2016 Time: 16:47 # 4
Blázquez et al. PL3, a New Chimeric Lysin
of choline concentration. To minimize errors, titrations were
carried out by serial addition of small volumes of concentrated
choline stocks to the same protein sample (less than 10% total
volume increase). Choline stock concentrations were measured
by differential refractometry (Usobiaga et al., 1996).
Analytical Ultracentrifugation
Sedimentation velocity experiments were carried out in an
Optima XL-A analytical ultracentrifuge (Beckman Coulter)
at 20◦C. Measurements were performed in PB, pH 6.8, at
45000 rpm using cells with double sector Epon-charcoal
centerpieces (0.11 mg/ml PL3). Differential sedimentation
coefficients were calculated by least-squares boundary modeling
of the experimental data, and normalized to values in water at
20◦C (s20,w), with the program SEDFIT (Brown and Schuck,
2006). The fractional friction coefficients (f/f 0) and the Stokes
radii (Rs), related to the protein hydrodynamic shape, were
calculated from the molecular masses and s20,w values using
the partial specific volumes and hydration coefficients estimated
from the amino acid sequence with the SEDNTERP program
(Laue et al., 1992).
Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry measurements were performed
at a heating rate of 60◦C/h in a VP-DSC microcalorimeter
(Microcal, Inc.), under an extra constant pressure of 1.8 atm, at
0.4 mg/ml PL3. Origin DSC software (Microcal) was used for
data acquisition and analysis. The excess heat capacity function
was obtained after subtraction of the buffer-buffer base line
registered before each protein scan. Reheating of previously
scanned samples showed that thermal denaturation of PL3 was
totally or partially irreversible, depending on the buffer pH.
In Vitro Cell Wall Activity Assay
Purified PL3 was checked for in vitro cell wall degradation
using [methyl-3H] choline-labeled pneumococcal cell walls as
substrate, following a previously described method (Mosser and
Tomasz, 1970). Briefly, 10 µl of enzyme at the appropriate
dilution was added to the reaction sample containing 240 µl
of PB, 100 mM NaCl, 10 mM DTT, pH 6.8, and 10 µl of
radioactively labeled cell walls (≈15000 cpm). After 15 min
incubation at 37◦C the reaction was stopped by adding 10 µl
formaldehyde (37%, v/v) and 10 µl bovine serum albumin (4%,
w/v). The pellet was removed by centrifugation (12000 × g,
15 min), and the enzymatic activity was quantified by measuring
the radioactivity in 200 µl of the supernatant with a liquid
scintillation counter (LKB Wallac). One unit of enzymatic activity
(U) was defined as the amount of enzyme that catalyzes the
hydrolysis (solubilization) of 1 µg of cell wall material in 15 min
(Höltje and Tomasz, 1976). Activity assays at different pHs were
performed in 20 mM sodium phosphate (pH 5.7–8.0) or 20 mM
HCl-Tris buffers (pH 8.0–9.0).
Bactericidal Assay
Log-phase bacteria were grown to an OD550 ≈ 0.3, cooled on
ice for 5 min, centrifuged, washed with PB, 100 mM NaCl, pH
6.8, and adjusted to an OD550 ≈ 0.6 (108–109 colony forming
units (CFUs) per ml) in the same buffer supplemented with
10 mM DTT. Afterward, resuspended bacteria were transferred
into plastic tubes and PL3 was added. Controls were always run
in parallel, replacing the added enzyme with buffer. Samples
were incubated at 37◦C for 1 h, the turbidity decrease (OD550)
was measured, and viable cells were determined using blood
agar plates at the end of incubation. For each sample, a 10-fold
dilution series was prepared, 10 µl of each dilution was plated,
and colonies were counted after overnight incubation at 37◦C.
Only dilutions with 30–300 colonies were considered, and in
assays where the bactericidal effect was high, 100 µl of undiluted
suspensions were plated and colonies counted.
Activity of PL3 in Different Phases of the
Growth Curve
Streptococcus pneumoniae R6 and P046 strains were incubated
until exponential phase of growth and diluted to an OD550
of 0.06. Then, cultures were divided in aliquots and PL3
(2.7 µg/ml, final concentration) was added at early exponential
phase (OD550 ≈ 0.15), late exponential phase (OD550 ≈ 0.4), or
stationary phase of growth (OD550≈ 0.7), with or without 10 mM
DTT in the medium. Viable cells of treated and untreated samples
were counted at 210 min after culture initiation, as explained
above.
Zebrafish Embryo Infection Assay
This study was conducted at The Zebrafish Lab1, using wild-type
zebrafish embryos that were maintained according to standard
protocols (Westerfield, 2007). Briefly, zebrafish embryos were
dechorionated at 24 h post fecundation by treatment with
pronase (2 mg/ml) for 2 min. At 48 h post fecundation, embryos
were individually distributed in 96-well plates and incubated in
50 µl of E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2
and 0.33 mM MgSO4, pH 7) at 28◦C in the presence of either
alive or heat-killed D39 pneumococcal cells (≈108 CFU/ml) for
8 h. The effect of adding 20 µg of PL3 or 1 mM DTT to
uninfected embryos was also tested. Afterward, infected embryos
were extensively washed with E3 medium, to remove bacteria,
transferred, together with the controls, to new 96-well microtiter
plates containing autoclaved E3 fresh medium supplemented
with different amounts of PL3 and 1 mM DTT — or the same
volume of buffer (controls) — before continuing incubation at
28◦C under sterile conditions. Mortality was followed in all
samples for 5 days, adding fresh E3 medium without DTT
every day. Zebrafish embryos were considered dead when no
movement was observed, even if a heartbeat was observed.
Opacification of the larvae was always found to follow shortly.
Bacterial infection was previously ascertained as the real cause of
embryo death by locating fluorescent bacterial signals around the
gills (Díez-Martínez et al., 2013).
Statistical Analysis
All data are representative of results obtained from repeated
independent experiments, and each value represents the
1http://www.thezebrafishlab.com
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mean ± standard deviations for three replicates. In the
case of the zebrafish embryo assay, the results from four
independent experiments were combined to evaluate a total
of 256 embryos for controls and for each lysin-treated group.
Statistical analysis was performed by using two-tailed Student’s t-
test (for two groups), whereas analysis of variance (ANOVA) was
chosen for multiple comparisons. GraphPad InStat version 3.0
(GraphPad Software, San Diego, CA, USA) was used for statistical
analysis.
RESULTS
Design and Production of the PL3
Chimera
The goal of this work was to construct a new chimeric
lysin specifically directed against S. pneumoniae and other
choline-containing Gram-positive bacteria, with higher activity
and stability than the parental enzymes. In this context, we
have recently shown how the substitution of the Cpl-7 CBD
by a different domain with higher affinity for the substrate
resulted in an extremely powerful lysin against pneumococci,
i.e., the Cpl-711 chimera (Díez-Martínez et al., 2015). With
this aim, we thoroughly analyzed the structural, enzymatic,
and bactericidal properties of natural and chimeric lysins from
the pneumococcal system, which includes the bacterium and
its phages. Thus, we decided to construct the PL3 chimera
by combining the catalytic Amidase_5 domain (PF05382) from
Pal, encoded by the bacteriophage Dp-1, and the C-terminal
region of the CBD from the major pneumococcal autolysin
LytA, which is a member of the Amidase_2 family (PF01510).
The approach was based on the following rationale: (i) both
lysins are effective antimicrobials against pneumococci (Jado
et al., 2003; Rodríguez-Cerrato et al., 2007); (ii) the catalytic
module of Pal is less negatively charged than that of LytA,
which might facilitate the lysis from the outside (Low et al.,
2011); (iii) saturation of choline-binding sites and choline-
induced dimerization, key for lytic activity, occur in LytA at
lower ligand concentration than in Pal (Medrano et al., 1996;
Varea et al., 2000, 2004); (iv) preservation of Pal overall modular
structure in the chimera could be achieved by conserving
the linker and the two first choline-binding repeats of Pal
(61% sequence identity to those of LytA); and (v) the new
chimera will combine the most structurally stable domains of
the parental enzymes: the CBD from LytA and the catalytic
domain of Pal (Varea et al., 2000, 2004). A comparative
scheme of PL3 and the parental Pal and LytA enzymes is
shown in Figure 1 whereas domain and linker charges are
given in Supplementary Figure S1 together with amino acid
sequence.
Cloning, overproduction and purification of PL3 were carried
out as detailed in the Section “Materials and Methods,” with
a yield of ≈110 mg per liter of culture. The protein eluted
from the DEAE-cellulose column showed two close bands (R
and O) when analyzed under non-reducing conditions by SDS-
PAGE. Nevertheless, the faster migrating band (O) disappeared
upon pretreatment of the sample with 10 mM DTT (or by
adding 1 mM β-mercaptoethanol) to the sample-loading buffer
(Figure 2A), and the remaining band (R) corresponded with
the expected mobility from the theoretical molecular mass
of PL3 (34287 Da) and the experimental value measured by
MALDI-TOFF mass (34151.3 Da; Met1 is processed). This
observation, indicative of an intra-molecular disulphide bridge
between the two cysteine residues (Cys34 and Cys112) of PL3
(and Pal) catalytic domain, was consistent with the stimulation
of Pal (García et al., 1983) and PL3 (see below) activities by
reducing agents. In addition, size-exclusion chromatography of
PL3 samples revealed the presence of different association states
(Figure 2B), including large protein aggregates eluting at the
void volume of the column (peak 1), and a likely oxidized form
of PL3 (peak 5) observed only when PB used for the protein
preequilibration did not contain β-mercaptoethanol. Therefore,
PL3 was subjected to a second purification step by size-exclusion
chromatography and all the experiments were performed under
reducing conditions with protein fractions comprised in peaks
2–4.
Preliminary in vitro assays using radioactive pneumococcal
cell walls or a suspension of R6 cells as substrates showed
that purified PL3 displayed high murolytic and bactericidal
activity and, thus, supported our hypothesis that PL3 could be a
promising weapon against pneumococci. Therefore, its structural
features, choline-binding affinity and structural stability were
characterized.
Characterization of PL3 Structure: Effect
of Choline Binding
Far- and Near-UV CD Spectra
The similarity of secondary and tertiary structures among the
chimera PL3 and the parental enzymes was analyzed by CD.
PL3 and Pal have very similar far-UV spectra (Figure 3A),
as expected from their identical catalytic domain and linker
and the high likeliness (77% sequence identity; 84% similarity)
of their CBDs. Main differences found when compared with
the LytA spectrum may be attributed to the different folds
of their unrelated catalytic domains. Indeed, the two positive
maxima displayed by PL3 and Pal spectra at 220–240 nm and
the negative band at 200 nm (a shoulder in the Pal spectrum)
likely correspond to a fingerprint of the Amidase_5 domain.
Choline binding strongly modified the far-UV spectra of PL3
and Pal; the intensity of the positive peak centered at 225–
224 nm was almost doubled, whereas the negative band at
200 nm was highly reduced (the ellipticity became positive
for the choline-bound form of Pal). The magnitude of such
variations strongly contrasts with the rather local effect of
choline binding on the LytA spectrum (the negative maximum
at 225 nm became positive upon choline addition). In the
near-UV region, largely dominated by the contributions of the
CBD aromatic side-chains and sensitive to the tertiary and
quaternary structures, the spectrum of unbound PL3 shows
features of both parental enzymes, but it reminds the choline-
bound spectra of LytA and Pal (Figure 3B). The likeness
increased upon choline addition, but the intensity of spectrum of
the choline-bound chimera was in between those of the parental
enzymes.
Frontiers in Microbiology | www.frontiersin.org 5 July 2016 | Volume 7 | Article 1156
fmicb-07-01156 July 26, 2016 Time: 16:47 # 6
Blázquez et al. PL3, a New Chimeric Lysin
FIGURE 1 | Schematic representation of the PL3 chimeric NAM-amidase and the parental Pal and LytA murein hydrolases. Domain and linker origin is
depicted by colors; gray and blue rectangles indicate the choline binding repeats comprised in Pal and LytA CBDs, respectively, followed by the C-terminal tail.
Numbers show the end of domains and linkers. The position of the two cysteine residues in Pal and PL3 catalytic domains is marked. Pfam entries for Amidase_2,
Amidase_5, and CW_binding_1 (choline-binding repeats) families are also shown.
Modulation of PL3 Association States by Choline
Binding
Like in other pneumococcal choline-binding proteins carrying a
CBD composed of six choline-binding repeats and a C-terminal
tail, choline binding regulates PL3 self-association, as depicted in
Figure 3C. The distribution of sedimentation coefficients (c(s∗))
of the unbound protein showed a mayor peak with an s20,w
of 6.8 S corresponding to the tetramer (Mw,app = 130 kDa),
a second peak compatible with the monomer (s20,w = 3.0;
Mw,app = 38 kDa) and a minor peak (≤5% total area) at
10.0 S. Choline addition induced PL3 dimerization (s20,w = 4.1
S; Mw,app = 64 kDa) with the subsequent reduction of monomer
and tetramer populations. At 5 mM choline and higher, the
dimer became the most favored form (≈80% at 0.11 mg/ml PL3)
although a small fraction of tetramer (10–12%) was still present.
Stabilization of PL3 dimer was concomitant with the saturation
of choline higher-affinity sites (see below), a feature shared
with LytA, though the most populated form of the unbound
autolysin was the dimer (Usobiaga et al., 1996; Varea et al.,
2000). In contrast, the predominant species of the unbound and
choline-bound forms of Pal were the monomer and the dimer,
respectively, which coexisted, however, with lower fractions of
higher association states (Varea et al., 2004). In addition, Pal
dimerization was enhanced by saturation of the lower affinity
sites (Varea et al., 2004). As shown in Supplementary Table S1,
the sedimentation coefficients, the frictional coefficient ratios
and Stokes radii calculated for a given state are almost identical
in the three lysins, considering the higher molecular mass of
the LytA monomer, which confirms that they have very similar
hydrodynamic shapes.
CD Titration of PL3 with Choline
The titration curve of PL3, obtained by representing the
relative variation in ellipticity at 295 nm as function of choline
concentration (Figure 3D), presents two well defined phases,
as in Pal and LytA (Medrano et al., 1996; Varea et al., 2004).
Saturation of the higher affinity sites required lower choline
concentration, compared to the parental enzymes, and correlated
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FIGURE 2 | Analysis of molecular forms of PL3. (A) Reducing and non-reducing SDS-PAGE profile of PL3. Protein equilibrated in PB or PB with 10 mM DTT was
loaded in the gel using sample buffer without (lanes 1 and 2, respectively) or with (lines 4 and 5, respectively) β-mercaptoethanol. Lane 3, standard molecular mass
markers. R and O arrows indicate bands corresponding to the reduced and oxidized form of PL3, respectively. (B) Size-exclusion fractioning of a PL3 sample, eluted
from the DEAE-cellulose column, dialyzed against PB, and pre-equilibrated in a Superose 12 HR/10/30 column with PB, pH 6.8, containing (thick solid trace) or not
(gray solid trace) 1 mM β-mercaptoethanol. Injection volume was 100 µl and the flow rate 0.5 ml/min. Large aggregates eluted in peak 1, whereas peak 5 likely
corresponds to the oxidized monomer of PL3.
with PL3 dimerization. The apparent half-dissociation constants
estimated through the description of PL3 titration profile in terms
of two sigmoid functions were 60 ± 9 µM and 4.5 ± 0.6 mM
for the higher and lower affinity sites, respectively, which are
slightly lower than those estimated, with the same approach,
for LytA (1.1 and 6.8 mM) and well below those of Pal (8 and
10 mM). In contrast, the cooperativity of choline binding to the
lower affinity sites was much higher in the two parental enzymes
(Supplementary Table S1).
Conformational Stability of PL3
Next, we analyzed the conformational stability of PL3 by DSC.
The thermal denaturation curves registered in PB at pH 6.8
showed a mayor peak centered at 53.6◦C with a shoulder at
the lower temperature side (Figure 4). The shift of the major
peak toward higher temperatures as choline concentration was
increased allowed its assignment to the CBD. Moreover, choline-
mediated stabilization eliminated the overlapping of the CBD and
catalytic domain transitions, the latter becoming fully resolved
with a transition temperature of 51◦C in the presence of 20 mM
choline. Like in Pal and LytA, the CBD stability increased at
slightly basic pHs (Usobiaga et al., 1996; Varea et al., 2000, 2004)
and was intermediate between those of the parental enzymes. As
expected from LytA and Pal stability profiles (Varea et al., 2000,
2004), denaturation of the catalytic domain of PL3 begun around
10◦C above that of LytA (Supplementary Figure S2).
Enzymatic Characteristics of PL3
Once characterized the biophysical properties related with the
lytic activity and structural robustness of PL3, we examined
its specific activity, very close to those of LytA and Pal
(Supplementary Figure S1), and the optimal conditions to either
degrade purified pneumococcal cell walls or kill R6 cells. Maximal
activity was displayed in PB, 100 mM NaCl, 10 mM DTT, pH
6.8, for the two assays, the effective range of lysis extending from
pH 6.5 to 8.0. These results were consistent with the optimal pH
values reported for Pal (pH 6.9) and LytA (pH 6.8; Sheehan et al.,
1997). The specific activity of PL3, 4 × 105 U/mg, was rather
similar to that found for the parental proteins, Pal and LytA
(Supplementary Figure S3). Remarkably,≈95% of PL3 murolytic
activity was maintained after been stored for 4 weeks at 37◦C, and
the bacteriolytic activity of the sample was fully preserved when
tested against resuspended R6 cells. Moreover, lyophilization of
PL3 did not provoke any loss of its murolytic and bacteriolytic
capacity (data not shown).
Bactericidal Activity of PL3
First, the antibacterial capacity of PL3 was tested against several
pneumococcal strains using the protocol described in the Section
“Materials and Methods,” which measures the turbidity decrease
of bacterial suspensions and the cell survival after 60 min of
incubation at 37◦C, with and without the lysin. PL3 reduced
the viability of all pneumococcal samples tested, including the
multiresistant clinical strain 48 (serotype 23F), leading to the
practical sterility of the cultures at concentrations of PL3 in
the range of 0.5–5 µg/ml (Figure 5). In strong contrast with
their similar lytic activities on purified cell walls (Supplementary
Figure S1B), PL3 kills pneumococci more effectively than Pal and
LytA, i.e., PL3 is capable to sterilize an R6 culture at 0.5 µg/ml,
whereas Pal and LytA reduced 5 and 7.5 log units the viable
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FIGURE 3 | Effect of choline binding on PL3 structure. Comparison of the far- (A) and near-UV (B) CD spectra of PL3, Pal, and LytA in the absence and in the
presence of 20 mM choline. (C) Effect of choline binding on PL3 association-state distribution. Increase of choline concentration shifts the monomer/dimer/tetramer
equilibria of PL3 toward the dimer (s20,w = 4.1 S) with the concomitant decrease of monomer (s20,w = 3.0) and tetramer (s20,w = 6.8 S) populations. Labels indicate
the choline concentration (mM). (D) CD titration curve of PL3 (squares) generated from the ellipticity changes induced at 295 nm by choline binding. Titration curves
of LytA (circles; Varea et al., 2000) and Pal (triangles; Varea et al., 2004) are also depicted. Continuous lines represent the fitting of experimental data as the sum of
two sigmoids with the parameters shown in Supplementary Table S1.
cells, respectively, but at 10-fold higher concentration (5 µg/ml;
Díez-Martínez et al., 2013). Moreover, at 0.1 µg/ml PL3 was even
more lethal than Cpl-1 and Cpl-711 lysozymes against R6 and
D39 strains, and as good as Cpl-711 against the multiresistant 48
strain (Díez-Martínez et al., 2015). It is worth noting that the type,
thickness and net charge of the different capsular polysaccharides
may somewhat modulate the lysin access to the peptidoglycan, as
deduced from the higher susceptibility of R6 to the killing action
of PL3 compared to that of the corresponding isogenic serotype-
2 encapsulated D39 strain. This conclusion is further supported
by the lower killing efficiency of PL3 obtained against P007, P008,
and 48 strains, belonging to serotypes 3, 4, and 23F, respectively
(Figure 5).
Since PL3 contains an specific CBD, it was feasible that this
chimera could also lyse other Gram-positive pathogens apart
from the pneumococcus, provided that they contain choline in
the (lipo)teichoic acids. Thus, the bactericidal activity of PL3 was
tested on various non-pneumococcal streptococci. As shown in
Figure 6, PL3 efficiently killed S. oralis, S. pseudopneumoniae,
and S. mitis type strains (harboring choline in their (lipo)teichoic
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FIGURE 4 | Thermal denaturation curves of PL3. DSC profiles of PL3
were measured in the absence and in the presence of choline at ligand
concentrations specified in figure labels. Experiments were performed at
0.4 mg/ml PL3 in PB, pH 6.8 (scan rate 60◦C/h). The curves were shifted
along the y-axis for clarity. CatD and CBD indicate the transitions
corresponding to the catalytic domain and the cell wall-binding domain,
respectively.
acids), although to eradicate the cells down to the limit of
detection it was necessary to add the enzyme at 5 µg/ml. As
expected, S. mitis SK598 strain, which possesses ethanolamine-
containing teichoic acids (Bergström et al., 2003), was refractory
to PL3 bacteriolytic action.
Effect of the Addition of PL3 to Different
Phases of the Growth Curve
After studying the exogenous bacteriolytic action of PL3 on
bacterial suspensions, we also investigated its effect along the
growing curve of R6 and the isogenic strain P046, a double
mutant lacking LytC and LytA autolysins, whose comparison
would allow evaluating the influence of endogenous autolysins
in PL3-mediated bacteriolysis. Thus, we added the same
concentration of PL3 (2.7 µg/ml) to different cultures of R6
or P046 at early exponential (OD550 ≈ 0.15), late exponential
(OD550 ≈ 0.4) and stationary phase of growth (OD550 ≈ 0.7) and
the turbidity decrease was monitored at 37◦C. Viable cells were
also determined 3.5 h after culture initiation. The addition of PL3
at any phase of the growth curve produced an immediate and
marked OD550 decrease, with the concomitant efficient killing of
both R6 and P046 cells (Figures 7A,B). Notably, the bactericidal
FIGURE 5 | Bactericidal activity of PL3 against pneumococcal strains.
Exponentially growing cultures were washed, resuspended in PB containing
100 mM NaCl and 10 mM DTT (pH 6.8), and treated with different
concentrations of PL3 for 60 min at 37◦C. Then, viable cells were measured
and killing value was calculated as the decrease of bacterial titers, in log units,
compared to PL3-untreated control. Protein concentrations (µg/ml) are
indicated in the x-axis. Error bars represent standard deviations and
differences in activity values are statistically significant (P < 0.05).
FIGURE 6 | Bactericidal activity of PL3 against non-pneumococcal
species. The assay was performed as described in Figure 5. Numbers on
x-axis indicate the concentration of PL3, in µg/ml. So, S. oralis; Sps,
S. pseudopneumoniae; SmT, S. mitis type strain; SmK, S. mitis SK598 strain.
Error bars represent standard deviations and differences in activity values are
statistically significant (P < 0.05).
effect depended on the strain and the growth phase; whereas PL3
addition sterilized R6 cultures at any point of the growing curve,
the number of viable cells for late exponential or stationary P046
cultures was reduced only 2 logs (Figure 7C). This difference
strongly suggests a synergistic effect between endogenous LytA
and LytC autolysins and exogenous PL3 to trigger cell lysis. It
is also noteworthy that when the experiment was carried out
without DTT in the media, the bacterial population can resume
growing again after an initial decrease in the OD550 and cell
survival was significantly increased, thereby demonstrating that
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FIGURE 7 | Effect of PL3 on growth of pneumococcal R6 and P046
cultures. (A,B) R6 and P046 growing curves where 2.7 µg/ml PL3 were
added at different phases of growth (marked by arrows) in the presence of
10 mM DTT. (C) Log of killed cells was calculated by comparing CFUs of
treated- and PL3-untreated cultures determined 210 min after culture
initiation. EE, early exponential phase; LE, late exponential phase; S, stationary
phase; C, untreated control. Error bars represent standard deviations and
differences in activity values are statistically significant (P < 0.05).
reducing conditions were necessary for the full activity of PL3
(data not shown).
Bactericidal Activity of PL3 in an
Infection Animal Model
The experiments described above proved that PL3 efficiently
kills pneumococci and relative bacteria in vitro. To validate
these data in vivo, we used the already set up zebrafish
embryo model for studying anti-streptococcal compounds (Díez-
Martínez et al., 2013). Zebrafish embryos were brought in contact
with the pneumococcal strain D39 by immersion in E3 medium
containing 1 mM DTT and incubated for 8 h at 28◦C, using heat-
killed D39 cells (10 min at 65◦C) as negative controls. Afterward,
embryos were extensively washed with E3 medium and treated
FIGURE 8 | Rescue of zebrafish embryos from pneumococcal infection
by PL3. Survival of embryos infected with D39 S. pneumoniae strain treated
or not with single doses of PL3. Data are means from four independent
experiments. Error bars represent standard deviation and asterisks mark the
results that are statistically significant for the overall comparison of infected or
PL3-treated embryos vs. the controls (one-way ANOVA with a post hoc
Dunnett test; ∗∗P < 0.001).
with different amounts of PL3, or the corresponding volume of
the enzyme buffer, as described in the Section “Materials and
Methods.” The mortality rate of infected embryos was around
40%, associated with inflammation of heart and liver, and death
occurred at about 48–72 h post-infection. Addition of a single
20-µg dose of PL3 to pneumococcus-infected embryos fully
protected them from death, whereas survival dropped to about
90% when treated with 15 µg (Figure 8). The level of protection
provided by PL3 was higher than those of Cpl-1 or Cpl-7S whose
complete protection of embryos was achieved at a dose of 25 µg
(Díez-Martínez et al., 2013).
DISCUSSION
The increased incidence of antibiotic resistance has led to a
renewed search for novel antimicrobials. In this context, the
use of pathogen-directed antibacterials through the employ of
specific lytic peptidoglycan hydrolases appears as an alternative
to diminish the rate of antibiotic-resistant pathogens worldwide
(Czaplewski et al., 2016). Most lysins reported as effective
antibacterials so far have a phage origin, encoded by lytic
(virulent) or temperate phages. Besides these “natural” genes
as source for lysins, another strategy is to combine catalytic
and substrate-binding domains from different origins to
construct fusion enzymes with novel bactericidal properties
or enhanced activity, solubility or stability (Donovan et al.,
2006; Daniel et al., 2010; Díez-Martínez et al., 2015; Yang
et al., 2015). Knowledge of the structural and functional
properties of selected domains and their compatibility with the
envelope structure of the targeted bacterium are key factors
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to successfully develop tailor-made lysins. Here we describe
the design, production and characterization of PL3, a robust
chimeric NAM-amidase constructed by substitution of the last
four choline binding repeats and the C-terminal tail of the
Pal endolysin by those of LytA NAM-amidase, the major
pneumococcal autolysin. Remarkably, PL3 bacteriolytic activity
from the outside goes beyond those of the parental lysins
against all the pneumococcal clones tested, including the 48
strain, which is resistant to penicillin, erythromycin, tetracycline,
and quinolones. Depending on the strain, PL3 compares, and
even surpasses, the bacteriolytic activity of Cpl-711, the more
effective enzybiotic against S. pneumoniae so far described (Díez-
Martínez et al., 2015). In contrast with some antibiotics, and
like other lysins, PL3 also has the advantage of being effective
against targeted bacteria at any metabolic state of the culture. In
particular, PL3 was able to kill bacteria at the stationary phase of
growth when the metabolic machinery, i.e., the level of protein
synthesis, was notably reduced. The antimicrobial efficacy of PL3
has been also validated in vivo using a zebrafish embryo infection
model, where a single dose of 20 µg fully protects against death
by infection with pneumococcal D39 strain.
PL3 exhibits also a potent lytic activity against
S. pseudopneumoniae, S. oralis, and S. mitis strains that
contain choline in the cell wall, which opens up its use to treat
the infections caused by these opportunistic pathogens. Namely,
S. pseudopneumoniae may cause pneumonia, bronchitis and
chronic sinusitis with greater resistance than pneumococcus to
several antimicrobials (Laurens et al., 2012). S. mitis can cause
a broad range of infections from caries to invasive diseases like
endocarditis, bacteremia, pneumonia, etc., with resistance to
common antibiotics (Mitchell, 2011). It is also an emergent
causative of blood infections in immunocompromised patients
(Shelburne et al., 2014) and has been associated to the toxic
shock syndrome with mortality rates above 60% (Tunkel and
Sepkowitz, 2002). Finally, S. oralis may produce bacterial
endocarditis, respiratory distress syndrome and streptococcal
shock in immunocompromised individuals (Verhagen et al.,
2006). It is also involved in periodontal disease, the most
common infection of the human oral cavity (Maeda et al., 2013).
In this respect, PL3 is the first lysin reported to effectively kill
S. oralis.
As expected from previous studies (Usobiaga et al., 1996; Varea
et al., 2004), modification of the CBD of Pal leading to the
PL3 chimera drastically enhanced choline binding and reduced
the concentration required for choline-induced dimerization,
two factors shown to be essential for the activity (Varea et al.,
2000), without perceptibly affecting the shape of the chimera
in relation to the equivalent association state of Pal or LytA.
Moreover, saturation of the higher affinity sites occurs in PL3
at lower choline concentration than in LytA, and these features
could explain, at least partially, the remarkable superiority of
PL3 in eradicating S. pneumoniae. These results might also
mean that the site located at the interface of the second
and third repeat, different in PL3, LytA and Pal, might be
central in choline recognition by the CBD. On the other hand,
the reduction of PL3 negative net charge in three units with
respect to LytA may further increase the bactericidal activity, by
facilitating the accessibility of PL3 to the peptidoglycan network
through the negatively charged outside of the bacteria (Low
et al., 2011; Díez-Martínez et al., 2013). Such effect might also
explain why the chimera and the parental lysins display highly
different relative activities when tested on bacterial suspensions
and very similar on purified pneumococcal cell walls, where
substrate fragmentation facilitates the accessibility and cleavage
of susceptible bonds.
Domain interchange conferred a remarkable conformational
robustness to PL3, evidenced by preservation of around 95%
activity when tested on purified pneumococcal cell walls or
bacterial suspension after been stored 4 weeks at 37◦C. Notably,
PL3 can even be lyophilized without any loss of activity when
assayed against the two types of substrates. Other interesting
finding of this study is the apparent cooperation of bacterial
autolysins to the exogenous bacteriolytic action of PL3, which
reminds the combined action of LytA and LytC with CbpD in
pneumococcal fratricide (Eldholm et al., 2009), and may open
new clues about the mechanism of action of lysins as anti-
infectives. Specifically, the absence of endogenous LytA and LytC
autolysins in pneumococcal P046 strain reduced by around 7 log
units the number of killed bacteria in relation with the isogenic
R6 strain, when exponential and stationary phase grown cultures
were treated with PL3.
Current evolution of the clinical trials is responding to the
initial hope of lysins as effective and specific alternative anti-
bacterials to fight most dangerous and multiresistant pathogens.
Indeed, the first commercial lysin is already on the market for
topical treatment of skin infections provoked by methicillin-
resistant Staphylococcus aureus (MRSA)2. Furthermore,
according to the portfolios of several pharmaceutical companies,
this example is expected to be followed by other lysins in
the near future. The results described in this work show that
structure and function-based approach to construct tailor-
made lysins by domain shuﬄing from parental proteins is an
advantageous alternative and it could be a general method
to design a ‘magic bullet’ directed against selected pathogens,
provided that in-depth knowledge on the enzymes and substrate
characteristics are in hand. In this sense, PL3 could be an
appropriate candidate, alone or in combination with other
active lysins, for the toolbox to combat multiresistant infections
provoked by any pneumococcal strain or closely related
pathogens.
CONCLUSION
We report here the design, production, and characterization
of PL3, a chimeric lysin with a robust bacteriolytic activity
in vivo and in vitro against S. pneumoniae and other streptococci
bearing choline in the cell wall. Due to its remarkable stability,
lyophilization feasibility, and killing efficiency at very low doses,
PL3 has a great potential to be used as an effective therapeutic
agent against susceptible and multiresistant pathogens.
2http://www.micreos.com/
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